Sowell Financial Services LLC Has $994,000 Holdings in Elevance Health, Inc. $ELV

Sowell Financial Services LLC boosted its position in shares of Elevance Health, Inc. (NYSE:ELV) by 142.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,835 shares of the company’s stock after buying an additional 1,664 shares during the period. Sowell Financial Services LLC’s holdings in Elevance Health were worth $994,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Artisan Partners Limited Partnership lifted its holdings in shares of Elevance Health by 24.5% during the 3rd quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company’s stock worth $1,478,857,000 after acquiring an additional 901,626 shares during the period. First Eagle Investment Management LLC lifted its holdings in shares of Elevance Health by 25.0% during the 3rd quarter. First Eagle Investment Management LLC now owns 3,998,603 shares of the company’s stock worth $1,292,029,000 after acquiring an additional 798,457 shares during the period. Brave Warrior Advisors LLC lifted its holdings in shares of Elevance Health by 65.3% during the 3rd quarter. Brave Warrior Advisors LLC now owns 1,834,002 shares of the company’s stock worth $592,603,000 after acquiring an additional 724,349 shares during the period. Baupost Group LLC MA lifted its holdings in shares of Elevance Health by 114.1% during the 3rd quarter. Baupost Group LLC MA now owns 1,319,000 shares of the company’s stock worth $426,195,000 after acquiring an additional 703,000 shares during the period. Finally, Hotchkis & Wiley Capital Management LLC lifted its holdings in shares of Elevance Health by 44.2% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 2,045,480 shares of the company’s stock worth $660,935,000 after acquiring an additional 627,038 shares during the period. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: CMS finalized a 2.48% Medicare Advantage payment rate for 2027 and officials noted about a 2.5% lift from risk‑adjustment changes—pushing the effective increase closer to ~5% and materially improving managed‑care revenue outlook. Elevance Health Stock Soars After 2.48% Medicare Rate Increase
• Positive Sentiment: Analysts are responding: Evercore reinstated coverage with an “in‑line” rating and a $345 price target (implying upside vs. recent levels), signaling renewed institutional interest. Elevance Health Reinstated at Inline by Evercore ISI
• Positive Sentiment: Bank of America updated its managed‑care outlook and raised its price target on ELV, supporting upside from improved policy tailwinds. BofA Updates Managed Care Outlook, Raises Elevance Health (ELV) Price Target
• Positive Sentiment: Several analysts and media pieces frame the CMS decision as a catalyst—some argue ELV is now attractively valued after a large share‑price decline and that technicals/valuation could support a rebound. Elevance Health: New Medicare Payment Rate A Gift, And The Chart Looks Good
• Neutral Sentiment: Coverage roundup and “top 5” lists highlight ELV as a beneficiary of the rate decision, which may attract rotation into health insurers but doesn’t change longer‑term fundamentals by itself. 5 Stocks That Should Benefit from the 2026 Medicare Advantage Rate Decision
• Neutral Sentiment: Company news items such as leadership changes and an upcoming earnings cycle are being discussed; these are watch‑items that could affect guidance/strategy but are not driving the immediate move. Will Elevance Health’s (ELV) Leadership Shuffle Refocus Its Core Advantage In Government Programs?
• Negative Sentiment: Some analysis reminds investors that ELV has faced structural headwinds (membership declines, higher benefit expense ratios) and has underperformed the market—a 1‑year ~27% slide keeps valuation/recovery risk on the table. Is It Time To Reassess Elevance Health (ELV) After A 27% One-Year Share Price Slide

Analysts Set New Price Targets

ELV has been the subject of a number of recent analyst reports. Guggenheim cut their price target on shares of Elevance Health from $414.00 to $396.00 and set a “buy” rating for the company in a report on Thursday, January 29th. Wolfe Research set a $425.00 price target on shares of Elevance Health and gave the stock an “outperform” rating in a report on Thursday, January 8th. Wells Fargo & Company cut their price target on shares of Elevance Health from $424.00 to $391.00 and set an “overweight” rating for the company in a report on Friday, January 30th. Jefferies Financial Group reduced their price target on shares of Elevance Health from $401.00 to $395.00 and set a “buy” rating on the stock in a research note on Friday, January 30th. Finally, Weiss Ratings downgraded shares of Elevance Health from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, February 2nd. Twelve investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $385.38.

Elevance Health Trading Up 2.1%

ELV opened at $318.39 on Thursday. The company’s 50 day moving average is $312.51 and its 200-day moving average is $332.18. Elevance Health, Inc. has a 1-year low of $273.71 and a 1-year high of $444.37. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.70. The company has a market cap of $69.94 billion, a P/E ratio of 12.67, a PEG ratio of 1.65 and a beta of 0.49.

Elevance Health (NYSE:ELV) last posted its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, beating analysts’ consensus estimates of $3.10 by $0.23. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The company had revenue of $49.31 billion for the quarter, compared to the consensus estimate of $49.52 billion. During the same period last year, the company posted $3.84 EPS. The firm’s quarterly revenue was up 9.6% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Equities research analysts predict that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.

Elevance Health Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th were paid a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date was Tuesday, March 10th. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s dividend payout ratio is 27.39%.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.